CBL mutation in childhood therapy-related leukemia
CBL mutation in childhood therapy-related leukemia
复制标题
儿童治疗相关白血病中的 CBL 突变
DOI：
10.1038/leu.2011.75
复制
发表时间：
2011
期刊：
影响因子：
11.4
通讯作者：
Hayashi Y.
中科院分区：
文献类型：
--
作者：
Shiba N;Taki T;Park MJ;Nagasawa M;Kanazawa T;Takita J;Ohnishi H;Sotomatsu M;Arakawa H;Hayashi Y.
2 Jinwal UK，Koren III J，Borysov SI，Schmid AB，Abisambra JF，Blair LJ等. The Hsp90 cochaperone，FKBP 51，increases Tau stability and polymerizes microtubules. J Neurosci 2010; 30：591-599. 3李丽，卢志，王丽。FKBP 5在癌症病因学和化学抗性中的作用Br J Cancer 2011; 104：19-23. 4 Pei H，Li L，弗里德利BL，Jenkins GD，Kalari KR，Lingle W等. FKBP 51通过负调节Akt影响癌细胞对化疗的反应. Cancer Cell 2009; 16：259-266. [5]裴华，娄志，王磊。FKBP 51在AKT激酶/蛋白激酶B信号传导中的新作用。细胞周期2010; 9：6-7。6 Rubnitz JE，Inaba H，Dahl G，Ribeiro RC，Bowman WP，Taub J et al.儿童急性髓性白血病的最小残留疾病导向治疗：AML 02多中心试验的结果。Lancet Oncol 2010;十一日：543-552.7 Lamba JK，Crews K，Pounds SB，Cao X，Gandhi V，Plunkett W等. Identification of predictive marker of acute myeloid leukemia of acytarabine response by integrative analysis of gene-expression profile with multiple phenotypes.药物基因组学2011; 12：327-239。8 Benjamini YaH，Hochberg Y.控制错误发现率：一种实用而有效的多重测试方法。J皇家统计学会，1995年。系列B。57：289-300。
2 Jinwal UK, Koren III J, Borysov SI, Schmid AB, Abisambra JF, Blair LJ et al. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J Neurosci 2010; 30: 591–599. 3 Li L, Lou Z, Wang L. The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer 2011; 104: 19–23. 4 Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009; 16: 259–266. 5 Pei H, Lou Z, Wang L. Emerging role of FKBP51 in AKT kinase/protein kinase B signaling. Cell Cycle 2010; 9: 6–7. 6 Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543–552.7 Lamba JK, Crews K, Pounds SB, Cao X, Gandhi V, Plunkett W et al. Identification of predictive markers of cytarabine response in acute myeloid leukemia by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 2011; 12: 327–239. 8 Benjamini YaH, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 1995. Series B. 57: 289–300.